US suture makers face product risk regrading
This article was originally published in Clinica
Manufacturers of eight categories of surgical sutures must conform with new performance, testing and labelling recommendations as of July 3, the FDA has announced. All of the sutures were on the market when the agency first obtained regulatory authority over devices in 1976, and as such were put in a transitional class III (high-risk) category until the FDA could decide on their appropriate classification.
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.